Despite the interest for the kickoff of recreational cannabis sales in Canada, the medical market has shown a consistent growth with new opportunities. A cannabis streaming company inked a deal with the potential to get ahead of the curve in the distribution of medical cannabis in Canada.
Cannabis Wheaton Income (TSXV:CBW), as president Hugo Alves told the Investing News Network (INN), was “willing to take a bet” and pursue an arrangement with a national chain of undisclosed independent pharmacies, announced on September 20.
After deciding they wanted to be a part of the way medical cannabis is distributed, Cannabis Wheaton’s research pointed them to the reach of pharmacies. As the deal stands, Cannabis Wheaton will monitor and control the retail space dedicated to medical cannabis, provided by their streaming partners. That is if this model becomes legal eventually.

Deal fringes on change in legality of distribution models for medical cannabis

When asked if he had any indication to be optimistic about an upcoming change in the law to allow this plan to come to fruition, Alves told INN he wasn’t aware of anything being done or discussed. Instead, Alves pointed to the differences between the distribution of recreational and medical cannabis.
“I know that pharmacies continue to be actively involved in trying to have their voice heard at a policy level,” Alves said. “We’re willing to take a bet that pharmacies will be included in the distribution channels for medical cannabis.”
This group, according to Alves operates 40 pharmacies in Canada and is focused on the construction of a “responsible retailing program,” that will serve consumers by providing them with education on cannabis products. Alves said this proposed model can become a viable supplement to the current delivery of medical cannabis.
Health Canada recently released a new batch of information on the number of medical cannabis users across the country. The data collected includes information for the first quarter of the fiscal 2017-2018 year, meaning April, May, and June.


Investor Takeaway

Set to be negotiated on a jurisdiction by jurisdiction basis, the potential profits from this deal will be distributed through a “profit-sharing arrangement.”
“In consideration for such exclusivity, Cannabis Wheaton will issue the Pharmacy Group warrants to purchase up to 1,000,000 common shares of the Company at an exercise price of $1.00 per common share for a period of 5 years,” the company announced.
This story has been updated to reflect the complete name of Cannabis Wheaton Income.
Don’t forget to follow us @INN_LifeScience and @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less